Fasenra® (benralizumab)

Fasenra (benralizumab) is covered only for its FDA‑approved uses — add‑on maintenance treatment of severe eosinophilic asthma in patients ≥6 years and treatment of adult eosinophilic granulomatosis with polyangiitis (EGPA) — and not for non‑approved indications. Coverage requires documented blood eosinophils ≥150 cells/µL (within 6 weeks for asthma, 4 weeks for EGPA or prior to any eosinophil‑lowering biologic), appropriate prescriber specialty (allergist/immunologist/pulmonologist; rheumatologist as applicable), for asthma ≥3 months of prior ICS+controller and evidence of uncontrolled disease (exacerbations, hospital/ER visits, FEV1 <80% or FEV1/FVC <0.80, or steroid‑dependence), and documented clinical response for reauthorization (≥6 months of Fasenra for asthma; ≥9 months and relapse/corticosteroid reduction or eosinophil reduction for EGPA), with initial asthma approval 6 months and renewals 12 months.

"Has an FEV1/forced vital capacity (FVC) less than 0."